目的:评价克拉霉素和阿莫西林与雷贝拉唑联用对胃溃疡患者的临床疗效及其对血清肿瘤坏死因子(TNF-α)、超敏C反应蛋白(Hs-CRP)、白介素-6(IL-6)等炎症指标的影响。方法:选取2013年5月—2016年5月收治的胃溃疡患者98例,将其分为观察组50例和对照组48例;观察组患者给予克拉霉素和阿莫西林与雷贝拉唑联用治疗,对照组患者给予奥美拉唑为基础的三联疗法,治疗14 d后两组患者继续服用雷贝拉唑及奥美拉唑4周,治疗结束后比较两组患者的总有效率和TNF-α、Hs-CRP、IL-6等炎症指标的影响。结果:治疗后,观察组患者TNF-α、HsCRP、IL-6等炎症指标优于对照组(P<0.05),幽门螺杆菌(HP)根治率为96.00%高于对照组为77.08%(P<0.05);经胃镜复查示观察组患者治疗后的总有效率为94.00%高于对照组为79.16%(P<0.05)。结论:采用克拉霉素和阿莫西林与雷贝拉唑联用治疗胃溃疡患者的效果较为显著,HP根治率较高,能有效改善炎症反应。 OBJECTIVE: To evaluate the clinical efficacy of clarithromycin and amoxicillin in combination with rabeprazole in the treatment of patients with gastric ulcer and its effect on serum tumor necrosis factor (TNF-α), high-sensitivity C-reactive protein (Hs-CRP), interleukin- 6 (IL-6) and other inflammatory markers. Methods: A total of 98 patients with gastric ulcer admitted from May 2013 to May 2016 were divided into observation group (50 cases) and control group (48 cases). Patients in the observation group were treated with clarithromycin, amoxicillin and rabeprazole Combination therapy, the control group of patients given omeprazole-based triple therapy, 14 days after treatment, two groups of patients continue to take rabeprazole and omeprazole for 4 weeks after treatment, the two groups compared the total effective rate And TNF-α, Hs-CRP, IL-6 and other inflammatory markers. Results: After treatment, the inflammation indexes of TNF-α, HsCRP and IL-6 in observation group were better than those in control group (P <0.05). The cure rate of Helicobacter pylori (HP) was 96.00%, which was higher than that of control group (77.08% <0.05). The total effective rate of observation group after treatment by gastroscopy was 94.00%, which was 79.16% (P <0.05). Conclusion: The effect of using clarithromycin and amoxicillin in combination with rabeprazole in the treatment of gastric ulcer patients is more obvious. The cure rate of HP is higher, which can effectively improve the inflammatory response.